
Tumor inflammatory response is significantly associated with poor prognosis in patients with multiple myeloma.
Tumor inflammatory response is significantly associated with poor prognosis in patients with multiple myeloma.
Researchers aim to eliminate leukemia stem cells safely.
Greater rates of adherence and persistence seen among patients on a single-tablet regimen.
Updated Carthadex trial results show improved responses at the 58-month mark and build on findings from other studies.
For their study, the authors wanted to expand on previous research results that suggest outcomes are improved among patients with multiple myeloma treated at high-volume facilities.
CDC recommends that young men who have sex with men have an HIV test every 6 months.
The rate of decrease in deaths from heart disease (HD) slowed between 2011 and 2014 versus 2000 and 2011, while the population above 65 years jumped 22.9% and there was a concurrent 38% rise in deaths from HD among this patient population.
A recently published commentary examined issues surrounding biosimilars in the treatment of multiple sclerosis from an international point of view, noting the tremendous opportunity for cost savings while wondering if patient concerns are being adequately considered.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.